AR086987A1 - 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia - Google Patents

1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia

Info

Publication number
AR086987A1
AR086987A1 ARP120102179A AR086987A1 AR 086987 A1 AR086987 A1 AR 086987A1 AR P120102179 A ARP120102179 A AR P120102179A AR 086987 A1 AR086987 A1 AR 086987A1
Authority
AR
Argentina
Prior art keywords
indanos
piperazino
deuterated
schizophrenia
phenyl
Prior art date
Application number
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR086987A1 publication Critical patent/AR086987A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Proceso para prepararlos, intermediarios de dicho proceso y preparación de los mismos.Reivindicación 1: Un compuesto de la fórmula (1), en donde R1 - R10 son, de modo independiente, hidrógeno o deuterio, en donde al menos uno de R1 - R10 comprende al menos aproximadamente el 50% de deuterio o una de sus sales por adición de ácidos farmacéuticamente aceptables. Reivindicación 19: Una composición farmacéutica que comprende el compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 18 y uno o varios portadores, diluyentes o excipientes farmacéuticamente aceptables.
ARP120102179 2011-06-20 2012-06-19 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia AR086987A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498651P 2011-06-20 2011-06-20
US201161537103P 2011-09-21 2011-09-21

Publications (1)

Publication Number Publication Date
AR086987A1 true AR086987A1 (es) 2014-02-05

Family

ID=46682855

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102179 AR086987A1 (es) 2011-06-20 2012-06-19 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia

Country Status (40)

Country Link
US (8) US8575174B2 (es)
EP (4) EP2720989B1 (es)
JP (1) JP5668177B2 (es)
KR (2) KR101879474B1 (es)
CN (1) CN103649019B (es)
AP (1) AP3310A (es)
AR (1) AR086987A1 (es)
AU (1) AU2012273657B2 (es)
BR (1) BR112013031702B1 (es)
CA (1) CA2837820C (es)
CL (1) CL2013003646A1 (es)
CO (1) CO6821965A2 (es)
CR (1) CR20130654A (es)
CY (2) CY1118158T1 (es)
DK (2) DK3135656T3 (es)
DO (1) DOP2013000305A (es)
EA (1) EA024651B1 (es)
EC (1) ECSP14013155A (es)
ES (3) ES2719145T3 (es)
GE (1) GEP201706655B (es)
GT (1) GT201300304A (es)
HK (1) HK1197228A1 (es)
HR (2) HRP20161348T1 (es)
HU (2) HUE044043T2 (es)
IL (1) IL229640B (es)
JO (1) JO3128B1 (es)
LT (2) LT2720989T (es)
MA (1) MA35268B1 (es)
MD (1) MD4538C1 (es)
ME (2) ME03375B (es)
MX (1) MX339552B (es)
MY (1) MY196998A (es)
PE (2) PE20150928A1 (es)
PL (2) PL2720989T3 (es)
PT (2) PT3135656T (es)
RS (2) RS58546B1 (es)
SI (2) SI3135656T1 (es)
SM (1) SMT201600383B (es)
TW (3) TWI614234B (es)
WO (1) WO2012176066A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2720989B1 (en) * 2011-06-20 2016-08-10 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
EP3679018B1 (en) 2017-09-07 2022-03-02 Otsuka Pharmaceutical Co., Ltd. Industrial process of mono-alkylating a piperidine nitrogen in piperidine derivatives with deuterated-alkyl
WO2020089147A1 (en) 2018-10-29 2020-05-07 H. Lundbeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
US11535600B2 (en) 2018-12-03 2022-12-27 H. Lundbeck A/S Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine
US20220106272A1 (en) * 2018-12-21 2022-04-07 Terran Biosciences, Inc. Deuterated Forms And Derivatives Of Volinanserin
CA3132953A1 (en) 2019-03-13 2020-09-17 Otsuka Pharmaceutical Co., Ltd. Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50867B1 (en) 1980-02-29 1986-08-06 Kefalas As Indane derivatives
GB8427125D0 (en) 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
DK286990D0 (da) 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
AU2004265022A1 (en) 2003-08-18 2005-02-24 H.Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
CN101935305B (zh) * 2003-08-18 2013-04-10 H.隆德贝克有限公司 反式-4-((1r,3s)-6-氯-3-苯基茚满-1-基)-1,2,2-三甲基哌嗪及其盐的制备方法及所用中间体
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
JP2008530039A (ja) 2005-02-16 2008-08-07 ハー・ルンドベック・アクチエゼルスカベット トランス−１−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩
CN101273024A (zh) 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
EP2998288B1 (en) 2005-12-01 2022-08-24 ACADIA Pharmaceuticals Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
JP4986462B2 (ja) 2006-01-27 2012-07-25 シャープ株式会社 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
WO2008128166A1 (en) 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
KR20100105802A (ko) 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
KR101185899B1 (ko) 2007-06-12 2012-09-27 콘서트 파마슈티컬즈, 인크. 아자펩티드 유도체
US20090062303A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched ziprasidone
CN102065861B (zh) 2008-05-07 2013-10-16 H.隆德贝克有限公司 反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途
EP2344163A1 (en) 2008-10-03 2011-07-20 H. Lundbeck A/S Oral formulation
WO2010062656A2 (en) 2008-10-28 2010-06-03 Concert Pharmaceuticals Inc. Deuterated 2-propylpentanoic acid compounds
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
US8658236B2 (en) * 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
CN102020522A (zh) * 2009-09-21 2011-04-20 陈松源 氘代药物的制备方法和应用
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
EP2720989B1 (en) * 2011-06-20 2016-08-10 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia

Also Published As

Publication number Publication date
MD4538B1 (ro) 2017-12-31
MA35268B1 (fr) 2014-07-03
PL2720989T3 (pl) 2017-05-31
CO6821965A2 (es) 2013-12-31
US20160068497A1 (en) 2016-03-10
RS55304B1 (sr) 2017-03-31
KR20180075717A (ko) 2018-07-04
PL3135656T3 (pl) 2019-07-31
EP4215512A1 (en) 2023-07-26
US20170158650A1 (en) 2017-06-08
EP3135656A1 (en) 2017-03-01
ME02513B (me) 2017-02-20
ME03375B (me) 2020-01-20
DK3135656T3 (en) 2019-04-23
HRP20161348T1 (hr) 2016-12-02
SMT201600383B (it) 2017-01-10
US10501427B2 (en) 2019-12-10
CR20130654A (es) 2014-03-24
TW201311248A (zh) 2013-03-16
EP3135656B1 (en) 2019-02-27
EP2720989B1 (en) 2016-08-10
SI3135656T1 (sl) 2019-05-31
IL229640B (en) 2018-02-28
US9012453B2 (en) 2015-04-21
HUE030883T2 (en) 2017-06-28
EP3508468A1 (en) 2019-07-10
LT3135656T (lt) 2019-04-25
MX339552B (es) 2016-05-31
KR101939546B1 (ko) 2019-01-16
TWI614234B (zh) 2018-02-11
PT3135656T (pt) 2019-05-03
DK2720989T3 (en) 2016-11-28
KR20140041567A (ko) 2014-04-04
HUE044043T2 (hu) 2019-09-30
GEP201706655B (en) 2017-04-25
GT201300304A (es) 2015-01-16
US11059798B2 (en) 2021-07-13
CL2013003646A1 (es) 2014-07-04
PT2720989T (pt) 2016-11-07
AP2013007338A0 (en) 2013-12-31
WO2012176066A1 (en) 2012-12-27
JP2014520140A (ja) 2014-08-21
HK1197228A1 (zh) 2015-01-09
MD4538C1 (ro) 2018-07-31
IL229640A0 (en) 2014-01-30
ES2719145T3 (es) 2019-07-08
SI2720989T1 (sl) 2016-11-30
US20130281436A1 (en) 2013-10-24
TWI627956B (zh) 2018-07-01
BR112013031702B1 (pt) 2021-11-03
TW201722895A (zh) 2017-07-01
CN103649019A (zh) 2014-03-19
JO3128B1 (ar) 2017-09-20
CA2837820C (en) 2019-02-19
MY196998A (en) 2023-05-17
EA201490045A1 (ru) 2014-07-30
US9617231B2 (en) 2017-04-11
US20220119362A1 (en) 2022-04-21
RS58546B1 (sr) 2019-05-31
NZ618222A (en) 2015-03-27
BR112013031702A2 (pt) 2016-12-13
US20190031631A1 (en) 2019-01-31
CA2837820A1 (en) 2012-12-27
KR101879474B1 (ko) 2018-07-17
PE20141113A1 (es) 2014-09-25
EA024651B1 (ru) 2016-10-31
AU2012273657B2 (en) 2016-07-21
MD20140004A2 (en) 2014-05-31
DOP2013000305A (es) 2014-02-28
LT2720989T (lt) 2016-11-25
PE20150928A1 (es) 2015-06-26
US8575174B2 (en) 2013-11-05
AU2012273657A1 (en) 2013-12-12
US10118907B2 (en) 2018-11-06
CY1118158T1 (el) 2017-06-28
US20120322811A1 (en) 2012-12-20
ES2939477T3 (es) 2023-04-24
TWI659741B (zh) 2019-05-21
EP2720989A1 (en) 2014-04-23
EP3508468B1 (en) 2023-01-18
HRP20190593T1 (hr) 2019-05-17
JP5668177B2 (ja) 2015-02-12
CY1121514T1 (el) 2020-05-29
MX2013014849A (es) 2014-03-31
ES2601213T3 (es) 2017-02-14
ECSP14013155A (es) 2014-02-28
US20150307458A1 (en) 2015-10-29
AP3310A (en) 2015-06-30
TW201902481A (zh) 2019-01-16
US20200131143A1 (en) 2020-04-30
CN103649019B (zh) 2015-09-16
US9216961B2 (en) 2015-12-22

Similar Documents

Publication Publication Date Title
AR086987A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
CR20170316A (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
UY35263A (es) Compuestos terapéuticos
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
CO6561783A2 (es) Inhibidores del virus flaviviridae
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
AR103222A1 (es) Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
DOP2014000121A (es) Derivados de betulina
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
DOP2012000151A (es) Nuevos compuestos triciclicos
ECSP13012438A (es) Proceso para preparar compuestos antivirales
CR20190504A (es) COMPUESTO DE AMIDA (Divisional 2015-0454)
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
DOP2012000243A (es) Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
IN2014MN02106A (es)
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
DOP2009000278A (es) Derivados de bencimidazol
ECSP14013239A (es) Composiciones farmacéuticas
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MA35841B1 (fr) Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ci

Legal Events

Date Code Title Description
FG Grant, registration